Safety and efficacy of biodegradable stents in octogenarian patients with esophageal achalasia

Abstract

Backgrounds and study aims Treatment of octogenarian patients with achalasia with conventional treatments is effective but with compromised safety. Biodegradable stents (BS) are promising. We aimed to evaluate their safety, efficacy and clinical outcomes at early, mid and long-term in this population.

Patients and methods Naïve or previously-treated achalasic octogenarian patients underwent to BS placement (BSP) between December, 2010 and November, 2011, and were followed-up for 9-years. A strict follow-up was performed.

Results Thirty-two patients were included, (17 men [53.1 %]; median age 82 years [78–92]). BSP was performed in all patients. At 9y, 18/32 (56.2 %) completed protocol. Mean BSP time was 37.5±12.1 min and 34.4 % presented thoracic pain. At 1 m, six BS were migrated (18.7 %), requiring a second BSP fixed with hemoclips. At 3 m, twenty-three (72.8 %) completed degradation process. At 6 m, eighteen (56.2 %) presented clinical dysphagia, of whom 5/32 (15.6 %) presented stenotic-tissue hyperplasia, responding to balloon dilation in all cases. Pre-BSP Eckardt, Timed barium esophagram and integrated relaxation pressure improved post-BSP 6 m values (9 vs 2, p = 0.001; < 50 % = 93.8 % vs > 80 % = 81.5 %, p = 0.003 and 18.8 ± 3.2 vs 11.1 ± 2.6 mmHg, p = 0.001, respectively), and there were no significant changes up to 9y post-BSP. Esophagitis grade A or B was presented between 4.7 % to 11.2 % and controlled with PPI. After 9 years we had clinical success rates of 94.4 %, 72 %, and 65.4 % for time point evaluation, per protocol and intention to treat analysis, respectively.

Conclusions BSP represents a feasible alternative option in octogenarian patients with achalasia who are high risk with other treatments, presenting acceptable early, mid-, and long-term outcomes.

Publikationsverlauf

Eingereicht: 23. November 2020

Angenommen: 05. Januar 2021

Artikel online veröffentlicht:
27. Mai 2021

• References

• 1 Swanström L. Achalasia: treatment, current status and future advances. Korean J Intern Med 2019; 34: 1173-1180
• 2 Cappell MS, Stravropoulos SM, Friedel D. Updated systematic review of achalasia, with a focus on POEM therapy. Dig Dis Sci 2020; 65: 38-65
• 3 Slone S, Kumar A, Jacobs J. et al. Accuracy of Achalasia Quality of life and Eckardt scores for assessment of clinical improvement post treatment for achalasia. Dis Esophagus 2020;
• 4 Vaezi MF, Pandolfino JE, Yadlapati RH. et al. ACG Clinical Guidelines: Diagnosis and Management of Achalasia. Am J Gastroenterol 2020; 115: 1393-1411
• 5 Fajardo RA, Petrov RV, Bakhos CT. et al. Endoscopic and surgical treatments for achalasia: who to treat and how?. Gastroenterol Clin North Am 2020; 49: 481-498
• 6 Xu S, Chai N, Tang N. et al. Outcomes of peroral endoscopic myotomy in challenging achalasia patients: a long-term follow-up study. Surg Endosc 2020;
• 7 Khashab MA, Vela MF, Thosani N. et al. ASGE guideline on the management of achalasia. Gastrointest Endosc 2020; 91: 213-227
• 8 Oude NijhuisRAB, Zaninotto G, Roman S. et al. European Guideline on Achalasia – UEG and ESNM recommendations. United European Gastroenterol J 2020; 8: 13-34
• 9 Doubova M, Gowing S, Robaidi H. et al. Long-term symptom control following laparoscopic Heller myotomy and Dor fundoplication for achalasia. Ann Thorac Surg 2020;
• 10 Facciorusso A, Singh S, Fehmi A. et al. Comparative efficacy of first-line therapeutic interventions for achalasia: a systematic review and network meta-analysis. Surg Endosc 2020;
• 11 Van Hoeij F, Tack J, Pandolfino J. et al. Complications of botulinum toxin injections for treatment of esophageal motility disorders. Dis Esophagus 2017; 30: 1-5
• 12 Cheng YS, Ma F, Li YD. et al. Temporary self-expanding metallic stents for achalasia: a prospective study with a long-term follow-up. World J Gastroenterol 2010; 16: 5111-5117
• 13 Zhao JG, Li YD, Cheng YS. et al. Long-term safety and outcome of a temporary self-expanding metallic stent for achalasia: a prospective study with a 13-year single-center experience. Eur Radiol 2009; 19: 1973-1980
• 14 Li TD, Cheng YS, Li MH. et al. Temporary self-expanding metallic stents and pneumatic dilation for the treatment of achalasia: a prospective study with long-term follow-up. Dis Esophagus 2010; 23: 361-367
• 15 Cai XB, Dai YM, Wan XJ. et al. Comparison between botulinum injection and removable covered self-expanding metal stents for the treatment of achalasia. Dig Dis Sci 2013; 58: 1960-1966
• 16 Coppola F, Gaia S, Rolle E. et al. Temporary endoscopic metallic stent for idiopathic esophageal achalasia. Surg Innov 2014; 21: 11-14
• 17 Lorenzo-Zúñiga V, Moreno-de-Vega V, Marin I. et al. Biodegradable stents in gastrointestinal endoscopy. World J Gastroenterol 2014; 20: 2212-2217
• 18 Hirdes MMC, Siersema PD, Van Boeckel PGA. et al. Single and sequential biodegradable stent placement for refractory benign esophageal strictures: a prospective follow-up study. Endoscopy 2012; 44: 649-654
• 19 Dua KS, Vleggaar FP, Santharam R. et al. Removable self-expanding plastic esophageal stent as a continuous, non-permanent dilator in treating refractory benign esophageal strictures: a prospective two-center study. Am J Gastroenterol 2008; 103: 2988-2994
• 20 Repici A, Vleggaar FP, Hassan C. et al. Efficacy and safety of biodegradable stents for refractory benign esophageal strictures: the BEST (Biodegradable Esophageal Stent) study. Gastrointest Endosc 2010; 72: 927-934
• 21 Hair CS, Devonshire DA. Severe hyperplastic tissue stenosis of a novel biodegradable esophageal stent and subsequent successful management with high-pressure balloon dilation. Endoscopy 2010; 42: E132-E133
• 22 Gkolfakis P, Siersema PD, Tziatzios G. et al. Biodegradable esophageal stents for the treatment of refractory benign esophageal strictures. Ann Gastroenterol 2020; 33: 330-337
• 23 Bredenoord AJ, Fox M, Kahrillas PJ. et al. Chicago classification criteria of esophageal motility disorders defined in high resolution esophageal pressure topography. Neurogastroenterol Motil 2012; 24: 57-65
• 24 Kahrilas PJ, Bredenoord AJ, Fox M. et al. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 2015; 27: 160-174
• 25 Eckardt VM, Aignherr C, Bernhard G. Predictors of outcome in patients with achalasia treated by pneumatic dilation. Gastroenterology 1992; 103: 1732-1738
• 26 Rezende JM. Classificacao radiológica do megaesófago. Rev Goiana Med 1982; 28: 187-191
• 27 Dakkak M, Bennett JR. A new dysphagia score with objective validation. J Clin Gastroenterol 1992; 14: 99-100
• 28 Cotton PB, Eisen GM, Aabakken L. et al. A lexicon for endoscopic adverse events: report of an ASGE workshop. Gastrointest Endosc 2010; 71: 446-454
• 29 Sanaka MR, Chadalavada P, Alomari M. et al. Peroral endoscopic myotomy is a safe and effective treatment modality for geriatric patients with achalasia. Esophagus 2020; 17: 484-491
• 30 Abe H, Tanaka S, Kawara F. et al. Comparison of the safety and efficacy of peroral endoscopic myotomy between octogenarians and non-octogenarians. Dig Endosc 2021; 33: 110-117
• 31 Chen Y, Inoue H, Ujiki M. et al. An international multicenter study evaluating the clinical efficacy and safety of per-oral endoscopic myotomy in octogenarians. Gastrointest endosc 2018; 87: 956-961
• 32 Rosen MJ, Novitsky YW, Cobb WS. et al. Laparoscopic Heller myotomy for achalasia in 101 patients: can successful symptomatic outcomes be predicted?. Surg Innov 2007; 14: 177-183
• 33 Finlayson EV, Birkmeyer JD. Operative mortality with elective surgery in older adults. Eff Clin Pract 2001; 4: 172-177
• 34 Zeng Y, Dai YM, Wan XJ. Clinical remission following endoscopic placement of retrievable, fully covered metal stents in patients with esophageal achalasia. Dis Esophagus 2014; 27: 103-108
• 35 Lundell LR, Dent J, Bennett JR. et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles Classiification. Gut 1999; 45: 172-180